KR101799005B1 - 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 - Google Patents
히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR101799005B1 KR101799005B1 KR1020160095326A KR20160095326A KR101799005B1 KR 101799005 B1 KR101799005 B1 KR 101799005B1 KR 1020160095326 A KR1020160095326 A KR 1020160095326A KR 20160095326 A KR20160095326 A KR 20160095326A KR 101799005 B1 KR101799005 B1 KR 101799005B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- alkyl
- synthesis
- methyl
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C(C)=*)N=IIC(C)=*C Chemical compound C[C@](C(C)=*)N=IIC(C)=*C 0.000 description 25
- ZTHGQBAUPMNVKT-UHFFFAOYSA-N COC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O Chemical compound COC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O ZTHGQBAUPMNVKT-UHFFFAOYSA-N 0.000 description 2
- QRDQCQSRGOUHRK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1S(N(Cc(nc1)ccc1C(OC)=O)c(cc1C)ccc1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1S(N(Cc(nc1)ccc1C(OC)=O)c(cc1C)ccc1F)(=O)=O)=O QRDQCQSRGOUHRK-UHFFFAOYSA-N 0.000 description 1
- VRPLJBRKXGRONA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1S(Nc(cc1C)ccc1F)(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1S(Nc(cc1C)ccc1F)(=O)=O)=O VRPLJBRKXGRONA-UHFFFAOYSA-N 0.000 description 1
- VFAZYPAOYUXHLT-UHFFFAOYSA-N CC(C)(CN(C)CC1)CN1S(NI)(=O)=O Chemical compound CC(C)(CN(C)CC1)CN1S(NI)(=O)=O VFAZYPAOYUXHLT-UHFFFAOYSA-N 0.000 description 1
- CFBZLUWOASRBQE-UHFFFAOYSA-N CC(C)(CN(CC1)S(NI)(=O)=O)C[N]1(C)C1CC1 Chemical compound CC(C)(CN(CC1)S(NI)(=O)=O)C[N]1(C)C1CC1 CFBZLUWOASRBQE-UHFFFAOYSA-N 0.000 description 1
- YIMYMZMBPHDTOB-UHFFFAOYSA-N CC(C)C(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(=O)=O)=O Chemical compound CC(C)C(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(=O)=O)=O YIMYMZMBPHDTOB-UHFFFAOYSA-N 0.000 description 1
- FFIHKZARVLWSBF-UHFFFAOYSA-N CC(C)N(CC1)CCN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CC(C)N(CC1)CCN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O FFIHKZARVLWSBF-UHFFFAOYSA-N 0.000 description 1
- XLCOBTYRMPFPIJ-UHFFFAOYSA-N CC(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1cccc(F)c1)(=O)=O)=O Chemical compound CC(N(CC1)CCN1S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1cccc(F)c1)(=O)=O)=O XLCOBTYRMPFPIJ-UHFFFAOYSA-N 0.000 description 1
- XMVNXQQETDBGFF-UHFFFAOYSA-N CC(N1CCN(CCN(C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)CC1)=O Chemical compound CC(N1CCN(CCN(C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)CC1)=O XMVNXQQETDBGFF-UHFFFAOYSA-N 0.000 description 1
- UXYQAZQKDRYBBE-UHFFFAOYSA-N CC/C=B\Cc(nc1)ccc1C(OC)=O Chemical compound CC/C=B\Cc(nc1)ccc1C(OC)=O UXYQAZQKDRYBBE-UHFFFAOYSA-N 0.000 description 1
- HBPXHBOXPPFFLL-HDICACEKSA-N CCN([C@H](C)C1)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CCN([C@H](C)C1)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O HBPXHBOXPPFFLL-HDICACEKSA-N 0.000 description 1
- SBXSUPAFTJURQE-UHFFFAOYSA-N CN(CCN1CCN(C)CC1)S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O Chemical compound CN(CCN1CCN(C)CC1)S(N(Cc(cc1)ccc1C(NN)=O)c1ccccc1)(=O)=O SBXSUPAFTJURQE-UHFFFAOYSA-N 0.000 description 1
- YRQCLNOYFTTWJY-UHFFFAOYSA-N CN(CCN1CCNCC1)S(N(Cc(cc1)ccc1C(OC)=O)c1ccccc1)(=O)=O Chemical compound CN(CCN1CCNCC1)S(N(Cc(cc1)ccc1C(OC)=O)c1ccccc1)(=O)=O YRQCLNOYFTTWJY-UHFFFAOYSA-N 0.000 description 1
- DIEYHLYBYAEFFZ-UHFFFAOYSA-N COC(Cc1ccc(CN(c2ccccc2)S(N2CCNCC2)(=O)=O)c(F)c1)=O Chemical compound COC(Cc1ccc(CN(c2ccccc2)S(N2CCNCC2)(=O)=O)c(F)c1)=O DIEYHLYBYAEFFZ-UHFFFAOYSA-N 0.000 description 1
- RNOFEBYIDNPCCX-UHFFFAOYSA-N COC(c1ccc(CN(c2cccc(Cl)c2)S(N2CCNCC2)(=O)=O)nc1)=O Chemical compound COC(c1ccc(CN(c2cccc(Cl)c2)S(N2CCNCC2)(=O)=O)nc1)=O RNOFEBYIDNPCCX-UHFFFAOYSA-N 0.000 description 1
- RACOLDKCUZXRSP-UHFFFAOYSA-N COC(c1ccc(CN(c2ccccc2)S(N(CC2)CCN2C2COC2)(=O)=O)c(F)c1)=O Chemical compound COC(c1ccc(CN(c2ccccc2)S(N(CC2)CCN2C2COC2)(=O)=O)c(F)c1)=O RACOLDKCUZXRSP-UHFFFAOYSA-N 0.000 description 1
- VTFFRINHSSWGGS-LBPRGKRZSA-N C[C@@H](CN(CC1)S(Nc2cccc(Cl)c2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN(CC1)S(Nc2cccc(Cl)c2)(=O)=O)N1C(OC(C)(C)C)=O VTFFRINHSSWGGS-LBPRGKRZSA-N 0.000 description 1
- JSYLJTSBBPHYGB-IYBDPMFKSA-N C[C@H](C1)N(C)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1cccnc1)(=O)=O Chemical compound C[C@H](C1)N(C)[C@@H](C)CN1S(N(Cc(cc1)ccc1C(NN)=O)c1cccnc1)(=O)=O JSYLJTSBBPHYGB-IYBDPMFKSA-N 0.000 description 1
- NRKCUFCCWXJAAY-IYBDPMFKSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(NN)=O)c2cnccc2)(=O)=O)N1C(C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(NN)=O)c2cnccc2)(=O)=O)N1C(C)=O NRKCUFCCWXJAAY-IYBDPMFKSA-N 0.000 description 1
- JXUODWWRSLAQRB-BGYRXZFFSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O JXUODWWRSLAQRB-BGYRXZFFSA-N 0.000 description 1
- RSCSFQXFGJJMJQ-CALCHBBNSA-N C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2cccnc2)(=O)=O)N1C(C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(N(Cc(cc2)ccc2C(OC)=O)c2cccnc2)(=O)=O)N1C(C)=O RSCSFQXFGJJMJQ-CALCHBBNSA-N 0.000 description 1
- JEKVYWBEVCXPET-OKILXGFUSA-N C[C@H](CN(C[C@@H]1C)S(Nc2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(Nc2ccccc2)(=O)=O)N1C(OC(C)(C)C)=O JEKVYWBEVCXPET-OKILXGFUSA-N 0.000 description 1
- YKUQSOROGCXWAT-BETUJISGSA-N C[C@H](CN(C[C@@H]1C)S(Nc2cccnc2)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(C[C@@H]1C)S(Nc2cccnc2)(=O)=O)N1C(OC(C)(C)C)=O YKUQSOROGCXWAT-BETUJISGSA-N 0.000 description 1
- KRMGKHXKGRBICV-UHFFFAOYSA-N Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N(CC2)CCN2C2CCC2)(=O)=O)ccc1F Chemical compound Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N(CC2)CCN2C2CCC2)(=O)=O)ccc1F KRMGKHXKGRBICV-UHFFFAOYSA-N 0.000 description 1
- ZONMQRYMGQTIBR-UHFFFAOYSA-N Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N2CCNCC2)(=O)=O)ccc1F Chemical compound Cc1cc(N(Cc(cc2)ccc2C(OC)=O)S(N2CCNCC2)(=O)=O)ccc1F ZONMQRYMGQTIBR-UHFFFAOYSA-N 0.000 description 1
- MVKSCNPSFAUQTD-UHFFFAOYSA-N NNC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O Chemical compound NNC(c1ccc(CN(c2cccc(Cl)c2)S(N(CC2)CCN2C2CCC2)(=O)=O)nc1)=O MVKSCNPSFAUQTD-UHFFFAOYSA-N 0.000 description 1
- DXQHZDLZGXUOHY-UHFFFAOYSA-N O=S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(N1CCNCC1)=O Chemical compound O=S(N(Cc(c(F)c1)ccc1-c1nnc(C(F)(F)F)[o]1)c1ccccc1)(N1CCNCC1)=O DXQHZDLZGXUOHY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150106177 | 2015-07-27 | ||
| KR1020150106177 | 2015-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170013186A KR20170013186A (ko) | 2017-02-06 |
| KR101799005B1 true KR101799005B1 (ko) | 2017-11-17 |
Family
ID=57885712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160095326A Active KR101799005B1 (ko) | 2015-07-27 | 2016-07-27 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464911B2 (https=) |
| EP (1) | EP3328844B1 (https=) |
| JP (1) | JP6538266B2 (https=) |
| KR (1) | KR101799005B1 (https=) |
| CN (1) | CN107980040B (https=) |
| AU (1) | AU2016299486B2 (https=) |
| BR (1) | BR112017027798B1 (https=) |
| CA (1) | CA2987570C (https=) |
| DK (1) | DK3328844T3 (https=) |
| ES (1) | ES2774510T3 (https=) |
| HR (1) | HRP20200280T1 (https=) |
| HU (1) | HUE048534T2 (https=) |
| MX (1) | MX376585B (https=) |
| MY (1) | MY194018A (https=) |
| NZ (1) | NZ736432A (https=) |
| PH (1) | PH12017501939B1 (https=) |
| PL (1) | PL3328844T3 (https=) |
| PT (1) | PT3328844T (https=) |
| RU (1) | RU2695227C9 (https=) |
| TW (1) | TWI694074B (https=) |
| WO (1) | WO2017018805A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| KR20180002729A (ko) | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| FI3328843T3 (fi) | 2015-07-27 | 2023-01-31 | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
| DK3330259T3 (da) | 2015-07-27 | 2020-08-10 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne |
| ES2774510T3 (es) | 2015-07-27 | 2020-07-21 | Chong Kun Dang Pharmaceutical Corp | Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos |
| RU2709207C2 (ru) | 2015-08-04 | 2019-12-17 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их |
| HRP20230201T1 (hr) | 2015-10-12 | 2023-03-31 | Chong Kun Dang Pharmaceutical Corp. | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CA3071825A1 (en) * | 2017-07-31 | 2019-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102059027B1 (ko) * | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3919055A4 (en) | 2019-01-30 | 2022-11-09 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| KR20220012243A (ko) | 2019-04-17 | 2022-02-03 | 퀴마트리스 에스.엘. | 히스톤 디아세틸라제 억제제로서의 1,3,4-옥사디아졸 유도체 |
| AU2020284606B2 (en) | 2019-05-31 | 2023-01-19 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| CN115443329A (zh) | 2019-06-27 | 2022-12-06 | 乔治华盛顿大学国会特许非营利公司 | Hdac6激活的巨噬细胞、其组合物及用途 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| MX2022003490A (es) * | 2019-09-27 | 2022-04-25 | Takeda Pharmaceuticals Co | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6). |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR102537616B1 (ko) * | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2023000625A (es) * | 2020-07-14 | 2023-02-22 | Chong Kun Dang Pharmaceutical Corp | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. |
| MX2023001086A (es) | 2020-08-07 | 2023-03-23 | Italfarmaco Spa | Nuevos inhibidores selectivos de histona desacetilasa 6 (hdac6) basados en oxadiazol. |
| KR102685058B1 (ko) | 2020-09-02 | 2024-07-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102905373B1 (ko) * | 2021-04-08 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물 |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| AU2022270657A1 (en) | 2021-05-04 | 2023-11-16 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| JP2025505686A (ja) * | 2022-02-08 | 2025-02-28 | ジョージタウン・ユニバーシティ | 選択的ヒストンデアセチラーゼ６阻害剤としての複素環式リンカーを有するａ１Ｈ－ベンゾ［ｃ］［１，２］チアジアジン－２，２－ジオキシド |
| KR102904231B1 (ko) * | 2022-04-07 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
| TW202412772A (zh) | 2022-07-19 | 2024-04-01 | 義大利商義大利藥品股份有限公司 | 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物 |
| CA3262628A1 (en) | 2022-08-08 | 2024-02-15 | Italfarmaco S.P.A. | HYDRAZIDES DIFLOORO- AND TRIFLUORO-ACETYLE USED AS SELECTIVE HDAC6 INHIBITORS |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| KR20240052687A (ko) * | 2022-10-14 | 2024-04-23 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 설폭시민 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| WO2012013716A1 (en) | 2010-07-29 | 2012-02-02 | Novartis Ag | Bicyclic acetyl-coa carboxylase inhibitors |
| US20120289495A1 (en) | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871753A (en) | 1986-12-12 | 1989-10-03 | Ciba-Geigy Corporation | 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2003028729A2 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| CN1289469C (zh) | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| BRPI0709110A2 (pt) | 2006-03-23 | 2011-06-28 | Prolysis Ltd | agentes antibacterianos |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| MX2009006202A (es) | 2006-12-11 | 2009-06-22 | Genentech Inc | Composiciones y metodos para el tratamiento de neoplasma. |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| EP2207811B1 (en) | 2007-11-02 | 2017-01-04 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| RU2515611C2 (ru) | 2008-07-23 | 2014-05-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы деацетилазы и их применение |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
| CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
| TWI600638B (zh) | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| CN103108867A (zh) | 2010-02-25 | 2013-05-15 | 皮拉马尔企业有限公司 | 噁二唑化合物及其制备和用途 |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2012076989A1 (en) | 2010-12-09 | 2012-06-14 | Wockhardt Limited | Ketolide compounds |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| CN103764635B (zh) | 2011-07-08 | 2016-01-20 | 诺华股份有限公司 | 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途 |
| US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| WO2013052110A1 (en) | 2011-10-03 | 2013-04-11 | The Trustees Of Columbia University In The City Of New York | Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| JP6272773B2 (ja) | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| CA2866707A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| SI3041828T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji |
| ES2704704T3 (es) * | 2013-12-12 | 2019-03-19 | Chong Kun Dang Pharmaceutical Corp | Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2016082930A1 (en) | 2014-11-24 | 2016-06-02 | Grünenthal GmbH | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| FI3328843T3 (fi) * | 2015-07-27 | 2023-01-31 | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
| ES2774510T3 (es) | 2015-07-27 | 2020-07-21 | Chong Kun Dang Pharmaceutical Corp | Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos |
| DK3330259T3 (da) | 2015-07-27 | 2020-08-10 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne |
| RU2709207C2 (ru) | 2015-08-04 | 2019-12-17 | Чонг Кун Данг Фармасьютикал Корп. | 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их |
| HRP20230201T1 (hr) | 2015-10-12 | 2023-03-31 | Chong Kun Dang Pharmaceutical Corp. | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste |
-
2016
- 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
- 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
- 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
- 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
- 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
- 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
- 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
- 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
- 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
- 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
- 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
- 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
- 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
- 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
- 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
- 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
- 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
- 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
- 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
- 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
-
2017
- 2017-10-24 PH PH12017501939A patent/PH12017501939B1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293530A1 (en) | 2006-06-14 | 2007-12-20 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| WO2010123933A1 (en) | 2009-04-20 | 2010-10-28 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| US20120289495A1 (en) | 2010-01-13 | 2012-11-15 | Tempero Pharmaceuticals Inc. | Compounds and methods |
| WO2012013716A1 (en) | 2010-07-29 | 2012-02-02 | Novartis Ag | Bicyclic acetyl-coa carboxylase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Bioorg Med Chem Lett., 2013.12., Vol.1, No.23, pp 6447-6454 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799005B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| KR101799009B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| US10538498B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| AU2016303891A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CN115210233B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CN115151542B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CN115427406B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CA3174319C (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2810081C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| RU2822624C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| HK40074260A (en) | 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| BR112018001716B1 (pt) | Composto de derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6 e composição farmacêutica contendo o mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160727 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170519 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171102 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171113 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20171113 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20200925 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20210927 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210927 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20220920 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220920 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230921 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240919 Start annual number: 8 End annual number: 8 |